drugset / Trial / NCT03939637

Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children

NCT03939637

RandomizedParallel-groupOpen-labelTreatment

Summary

This is an investigator initiated, multicenter, open label, randomized phase 3 study for subjects with newly diagnosed ITP from ages 1 to less than 18 years old.

Timeline

Start
2019-05-02
Primary completion
2024-04-17
Completion
2025-02-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Eltrombopag Small molecule 25 mg Oral
Subject Eltrombopag Small molecule 50 mg Oral
Comparator Immune Globulin Intravenous (Human) Protein / enzyme biologic 1 g/kg Intravenous
Comparator Prednisolone Other / unclassified 4 mg/kg
Comparator Prednisone Other / unclassified 4 mg/kg
Comparator Rho(D) Immune Globulin Unknown 75 ug/kg